Published on October 23, 2009 at 1:40 AM
Cempra Pharmaceuticals today announced its schedule of oral and poster presentations at the Infectious Disease Society of America, 47th Annual Meeting, in Philadelphia on Oct. 29 to Nov. 1, 2009.
Four presentations on CEM-102 will present results on the compound's in vitro activity against gram-positive organisms, featuring resistance frequencies, and the drug's PK-PD profile when a novel dosing regimen is used. A fifth presentation will present in vitro data on CEM-101's activity against multidrug-resistant S. pneumoniae.
CEM-102 is an oral formulation of fusidic acid, an agent with activity against gram-positive organisms including methicillin-resistant S. aureus (MRSA). The compound is Cempra's lead molecule currently in Phase 2/3 clinical trials, vs. linezolid, being investigated for the treatment of acute bacterial skin structure infections (ABSSIs). This novel adaptive trial is expected to flow into a Phase 3 pivotal trial in Q1 2010. CEM-101, Cempra's novel oral fluoroketolide, will soon enter a Phase 2 clinical trial for moderate-to-moderately severe community-acquired bacterial pneumonia (CABP). CEM-101 has shown potent activity against S. pneumoniae, including multidrug-resistant isolates.
SOURCE Cempra Pharmaceuticals